Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gregory Videtic

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
International Journal of Radiation Oncology, Biology, Physics|June 26, 2025
Unmasking Collapse: Navigating Airspace Changes During RadiationAdannia Ufondu, Gregory Videtic
Lung Cancer (Amsterdam, Netherlands)|June 21, 2018
Low level evidence supporting the choice of optimal multimodality treatment approach in patients with stage IIIA NSCLC- Ain't no mountain high enough…. to keep me getting to youBranislav Jeremic, Antonio Gomez-Caamano, Pavol Dubinsky, et al.
Journal of Applied Clinical Medical Physics|December 25, 2015
Dose differences in intensity-modulated radiotherapy plans calculated with pencil beam and Monte Carlo for lung SBRTHan Liu, Tingliang Zhuang, Kevin Stephans, et al.
Journal of Applied Clinical Medical Physics|March 9, 2013
Dose calculation differences between Monte Carlo and pencil beam depend on the tumor locations and volumes for lung stereotactic body radiation therapyTingliang Zhuang, Toufik Djemil, Peng Qi, et al.
Journal of Radiation Research|March 25, 2017
Combined modality therapy in Stage IIIA non-small cell lung cancer: clarity or confusion despite the highest level of evidence?Branislav Jeremic, Francesc Casas, Pavol Dubinsky, et al.
Frontiers in Oncology|March 13, 2018
Treatment-Related Predictive and Prognostic Factors in Trimodality Approach in Stage IIIA/N2 Non-Small Cell Lung CancerBranislav Jeremić, Francesc Casas, Pavol Dubinsky, et al.
Clinical Lung Cancer|May 10, 2011
Phase I/II trial of a COX-2 inhibitor with limited field radiation for intermediate prognosis patients who have locally advanced non-small-cell lung cancer: radiation therapy oncology group 0213Elizabeth Gore, Kyounghwa Bae, Corey Langer, et al.
Advances in Radiation Oncology|November 9, 2017
<i>ASTRO's Advances in Radiation Oncology</i>: Success to date and future plansRobert C Miller, Sharad Goyal, Shearwood McClelland, et al.
Cleveland Clinic Journal of Medicine|May 2, 2022
Esophageal adenocarcinoma: A dire need for early detection and treatmentAbel Joseph, Siva Raja, Suneel Kamath, et al.
JCO Oncology Practice|December 9, 2025
Fifteen-Year National Trends in Single-Fraction Stereotactic Body Radiation Therapy Utilization for Stage I Non-Small Cell Lung CancerDrew Moghanaki, Gregory Videtic, Anurag K Singh, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
International Journal of Radiation Oncology, Biology, Physics|June 26, 2025
Unmasking Collapse: Navigating Airspace Changes During RadiationAdannia Ufondu, Gregory Videtic
Lung Cancer (Amsterdam, Netherlands)|June 21, 2018
Low level evidence supporting the choice of optimal multimodality treatment approach in patients with stage IIIA NSCLC- Ain't no mountain high enough…. to keep me getting to youBranislav Jeremic, Antonio Gomez-Caamano, Pavol Dubinsky, et al.
Journal of Applied Clinical Medical Physics|December 25, 2015
Dose differences in intensity-modulated radiotherapy plans calculated with pencil beam and Monte Carlo for lung SBRTHan Liu, Tingliang Zhuang, Kevin Stephans, et al.
Journal of Applied Clinical Medical Physics|March 9, 2013
Dose calculation differences between Monte Carlo and pencil beam depend on the tumor locations and volumes for lung stereotactic body radiation therapyTingliang Zhuang, Toufik Djemil, Peng Qi, et al.
Journal of Radiation Research|March 25, 2017
Combined modality therapy in Stage IIIA non-small cell lung cancer: clarity or confusion despite the highest level of evidence?Branislav Jeremic, Francesc Casas, Pavol Dubinsky, et al.
Frontiers in Oncology|March 13, 2018
Treatment-Related Predictive and Prognostic Factors in Trimodality Approach in Stage IIIA/N2 Non-Small Cell Lung CancerBranislav Jeremić, Francesc Casas, Pavol Dubinsky, et al.
Clinical Lung Cancer|May 10, 2011
Phase I/II trial of a COX-2 inhibitor with limited field radiation for intermediate prognosis patients who have locally advanced non-small-cell lung cancer: radiation therapy oncology group 0213Elizabeth Gore, Kyounghwa Bae, Corey Langer, et al.
Advances in Radiation Oncology|November 9, 2017
<i>ASTRO's Advances in Radiation Oncology</i>: Success to date and future plansRobert C Miller, Sharad Goyal, Shearwood McClelland, et al.
Cleveland Clinic Journal of Medicine|May 2, 2022
Esophageal adenocarcinoma: A dire need for early detection and treatmentAbel Joseph, Siva Raja, Suneel Kamath, et al.
JCO Oncology Practice|December 9, 2025
Fifteen-Year National Trends in Single-Fraction Stereotactic Body Radiation Therapy Utilization for Stage I Non-Small Cell Lung CancerDrew Moghanaki, Gregory Videtic, Anurag K Singh, et al.
Pageof 3